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A large-scale RNA interference 
screen identifies genes that 
regulate autophagy at different 
stages
Sujuan Guo1, Kevin J. Pridham1,2, Ching-Man Virbasius3, Bin He4, Liqing Zhang4, Hanne Varmark5, 
Michael R. Green3 & Zhi Sheng1,6,7,8
Dysregulated autophagy is central to the pathogenesis and therapeutic development of cancer. 
However, how autophagy is regulated in cancer is not well understood and genes that modulate 
cancer autophagy are not fully defined. To gain more insights into autophagy regulation in cancer, 
we performed a large-scale RNA interference screen in K562 human chronic myeloid leukemia 
cells using monodansylcadaverine staining, an autophagy-detecting approach equivalent to 
immunoblotting of the autophagy marker LC3B or fluorescence microscopy of GFP-LC3B. By coupling 
monodansylcadaverine staining with fluorescence-activated cell sorting, we successfully isolated 
autophagic K562 cells where we identified 336 short hairpin RNAs. After candidate validation using 
Cyto-ID fluorescence spectrophotometry, LC3B immunoblotting, and quantitative RT-PCR, 82 genes 
were identified as autophagy-regulating genes. 20 genes have been reported previously and the 
remaining 62 candidates are novel autophagy mediators. Bioinformatic analyses revealed that most 
candidate genes were involved in molecular pathways regulating autophagy, rather than directly 
participating in the autophagy process. Further autophagy flux assays revealed that 57 autophagy-
regulating genes suppressed autophagy initiation, whereas 21 candidates promoted autophagy 
maturation. Our RNA interference screen identifies identified genes that regulate autophagy at 
different stages, which helps decode autophagy regulation in cancer and offers novel avenues to 
develop autophagy-related therapies for cancer.
Autophagy (also known as macroautophagy) is a subcellular catabolic process where cytoplasm and organelles 
are digested, and metabolic products are recycled to prolong cell survival under conditions of stress. Autophagy 
is characterized by the formation of autophagosomes (autophagy initiation) followed by fusion with lysosomes. 
The resulting autolysosomes degrade and recycle engulfed materials (autophagy maturation). This entire dynamic 
process is termed as autophagy flux. While autophagy often protects cells, excessive digestion triggers autophagic 
cell death. Hence, autophagy is critical for maintaining homeostasis and is central to the pathogenesis of many 
human diseases including cancer1–4.
Mounting evidence has established a fundamental role of autophagy in tumor initiation and progression5. As 
such, targeting autophagy as a means for cancer therapeutic development has been widely explored6–9. However, 
the relationship between autophagy and cancer therapeutic responses is complicated. On one hand, autophagy 
activators are appealing cancer drugs because excessive autophagy induces autophagic cell death. Many cancer 
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signaling pathways such as PI3K/MTOR (phosphatidylinositol-4,5-bisphosphate 3-kinase/mechanistic target of 
rapamycin)10–13 or RAS (rat sarcoma viral oncogene homolog)14,15 suppress autophagy. However, targeting these 
kinases or small GTPase to specifically activate autophagic cell death has been proven difficult because of their 
important roles in other cell death pathways such as apoptosis6,16,17. On the other hand, established cancer often 
maintains a proficient level of autophagy to sustain cancer cell survival18, making autophagy blockade an attrac-
tive strategy to break this protection. Inhibition of autophagy can be achieved either by blocking autophagy ini-
tiation characterized by formation of autophagosomes or by impairing autophagy maturation to halt autophagy 
flux. Targeting autophagy maturation to block autophagy flux has been used in treating cancer. For example, 
chloroquine blocks the activity of autolysosomes to impede autophagy flux19. In combination with conventional 
therapies, this drug has prolonged the survival of glioblastoma patients; however, the statistical significance was 
low20. In addition, chloroquine exhibits severe side effects in the clinic limiting its application as an effective 
cancer treatment21,22. Many efforts have been invested to find new strategies to tackle autophagy with limited suc-
cess, largely because autophagy regulation in cancer is not well understood and genes that regulate this dynamic 
process are not fully defined.
Chronic myeloid leukemia (CML) is characterized by the production of a single oncogenic protein BCR-ABL, 
which results from the translocation between chromosome 9 and 2223. Imatinib and its derivatives, the spe-
cific inhibitors of BCR-ABL, have been used in the clinic to treat CML24; however, resistance that is either 
BCR-ABL-dependent (i.e. BCR-ABL mutations) or -independent still develops in patients25. One possible reason 
for BCR-ABL-independent imatinib resistance is that CML cells activate autophagy to sustain their survival dur-
ing imatinib treatment26–29. In our previous study, we show that BCR-ABL suppresses autophagy through activat-
ing a transcription factor called activating transcription factor 5 (ATF5), which in turn transcriptionally activates 
the expression of MTOR. Blocking ATF5 sensitizes CML cells to imatinib26,28. Based upon these results, it is 
imperative to identify novel autophagy regulators in CML so as to not only gain deeper insights into autophagy 
regulation but also provide novel therapeutic targets to develop effective autophagy-related therapies for cancer.
In this report, we isolated autophagic K562 cells using the fluorescent dye, monodansylcadaverine (MDC), 
coupled with fluorescence-activated cell sorting (FACS). The sensitivity of this approach in detecting autophagy 
was similar to other autophagy-detecting approaches such as LC3B immunoblotting and Cyto-ID fluorescence 
spectrophotometry. We carried out a large-scale RNA interference (RNAi) screen followed by rigorous multistep 
validations. We identified 82 genes that regulate autophagy in K562 cells. Among these genes, 62 candidates are 
novel autophagy regulators. Furthermore, we revealed that these genes either suppress autophagy initiation or 
promote autophagy maturation. Our results have important implications in understanding fundamental mecha-
nisms of autophagy regulation in cancer and in the development of effective cancer therapies.
Results
MDC stains autophagic K562 cells. Labeling and isolating live autophagic cells is difficult30. To resolve 
this issue, we employed a fluorescent dye MDC that labels acidic compartments including autolysosomes31. To 
stain live autophagic cells with MDC, we treated K562 cells with 1 μM imatinib (IM) to induce autophagy in 
K562 cells as described in our previous report26. We then stained K562 cells with MDC and monitored MDC 
fluorescence in live cells using an inverted fluorescence microscope. MDC fluorescence was in low levels and 
barely detected in live K562 cells treated with DMSO (top panel), whereas strong MDC fluorescence was detected 
in IM-treated cells (Fig. 1A, bottom panel). To corroborate these results and quantitatively measure MDC fluo-
rescence, we carried out a spectrophotometric assay using a microplate reader. IM significantly enhanced MDC 
fluorescence intensities by approximately 2-fold (Fig. 1B). LC3B (microtubule associated protein 1 light chain 3 
β, MAP1LC3B) is an autophagy marker. Immuno-detection of the lapidated lipidated form of LC3B (LC3B-II) 
located on the membrane of autophagosomes and GFP-LC3B fluorescence microscopy that monitors the forma-
tion of autophagosomes (GFP-LC3B puncta) are well-established autophagy assays32,33. We determined levels of 
LC3B-II in K562 cells treated with DMSO or IM. IM induced a 1.4-fold increase of LC3B-II (Fig. 1C), similar to 
the fold changes of MDC fluorescence. Hence, the sensitivity of MDC in labeling autophagic cells is equivalent 
to that of LC3B. To determine whether MDC staining can be used to measure autophagy flux, we treated K562 
cells with IM and bafilomycin A1 (BFA1), a selective inhibitor of vacuolar H+ ATPase that prevents the fusion 
of autophagosomes and lysosomes. Cells treated with both IM and BFA1 showed much stronger MDC fluores-
cence (Fig. 1D). Quantification revealed that the co-treatment of IM and BFA1 significantly enhanced MDC 
intensities compared to each treatment alone (Fig. 1E). To compare MDC staining with GFP-LC3B fluorescence 
microscopy, we transfected K562 cells with GFP-LC3B followed by the treatment of IM and/or BFA1. IM and 
BFA1 significantly increased percentages of cells with GFP-LC3B puncta (Fig. 1F,G), congruent with results of 
MDC staining (Fig. 1D,E). We did notice that the background levels of MDC staining were much higher than 
those of GFP-LC3B puncta. However, GFP-LC3B fluorescence microscopy is based on the morphological changes 
of GFP-LC3B rather than fluorescence intensity. As such, GFP-LC3B-based assays are not suitable for isolating 
autophagic cells using FACS. While MDC may stain cells with enhanced levels of both lysosomes and autolyso-
somes (see discussion for details), this approach is compatible with FACS and suitable for high-content studies. 
In addition, our results shown above demonstrate that MDC staining can be used to determine autophagy and 
autophagy flux at least in K562 cells upon IM treatment. We therefore used MDC staining coupled with FACS to 
isolate autophagic K562 cells in the following experiments.
A genome-wide RNAi screen identifies novel autophagy-regulating genes. Next, we employed 
MDC staining followed by FACS in a genome-wide RNAi screen designed for identifying novel autophagy reg-
ulators. As illustrated in Fig. 2A, K562 cells were transduced with a library of 75,000 shRNAs that target nearly 
15,000 human genes. After isolation of autophagic cells using MDC and FACS, genomic DNAs that harbor shR-
NAs were extracted. shRNAs were PCR-amplified using pre-designed primers, and subsequently identified using 
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Figure 1. Monodansylcadaverine (MDC) stains autophagic K562 cells with sensitivity equivalent to LC3B 
immunoblotting and GFP-LC3B fluorescence microscopy. (A) Fluorescence microscopy. K562 cells were 
treated with dimethyl sulfoxide (DMSO) or 1 μM imatinib (IM) overnight followed by MDC staining. Images of 
live cells were taken at different exposure times (milliseconds, ms) using an inverted fluorescence microscope. 
Scale bar: 25 μm. (B) MDC Fluorescence spectrophotometry. K562 cells treated with DMSO or IM were 
stained with MDC. MDC fluorescence of live K562 cells was quantified using a micro-plate reader at an 
excitation wavelength of 335 nm and an emission wavelength of 525 nm. The relative MDC levels were obtained 
by dividing MDC fluorescence of IM-treated cells to that of DMSO-treated cells. Error bars represent three 
independent experiments. (C) LC3B immunoblotting. Cropped images are shown and full images are included 
in supplemental materials. ACTB (β actin) is the loading control. The intensities of LC3B-II or ACTB were 
quantified using Image J. The fold changes of LC3B-II/ACTB were obtained by dividing the ratio of LC3B-II/
ACTB in IM-treated cells with that of DMSO-treated cells. (D) MDC staining of K562 cells treated with IM 
and/or bafilomycin A1 (BFA1). K562 cells were treated with a combination of 1 μM IM (10 hours) and 5 nM 
of BFA1 (48 hours). Cells were imaged using a fluorescence confocal microscope. (E) Quantification of MDC 
intensities. Fluorescence intensities of MDC in 10 different cells from three images were quantified using Image 
J. (F) GFP-LC3B fluorescence microscopy. K562 cells were stably transfected with a construct encoding GFP-
LC3B. Cells were treated with a combination of IM and BFA1 and then imaged. (G) Quantification of cells 
with GFP-LC3B puncta. Four to five images of more than thirty K562 cells from each treatment were randomly 
selected for the following quantification analyses. GFP-expressing K562 cells or K562 cells with GFP puncta 
(indicating autophagy) were counted by three persons. Percentages of K562 cells with puncta were obtained by 
dividing numbers of K562 cells with GFP puncta with those of GFP-expressing cells. Scale bar: 25 nm.
www.nature.com/scientificreports/
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Sanger DNA sequencing. In more than 500 individual PCR products, we identified 336 shRNAs (Fig. 2A and 
Table S1) and more than 50 shRNAs were repeatedly sequenced.
To further validate these candidates we employed another fluorescent dye, Cyto-ID, which specifically labels 
autophagosomes, amphisomes, and autolysosomes with minimal staining of lysosomes34,35. We transduced K562 
cells with viruses containing individual shRNAs or a control non-silencing (NS) shRNA. Autophagy was meas-
ured using the Cyto-ID fluorescence spectrophotometric assay we have recently developed34,35. Among 336 can-
didates, 152 shRNAs induced a ≥ 1.4-fold increase of Cyto-ID fluorescence, compared to NS shRNA (Fig. 2B and 
Table S1). We next utilized LC3B immunoblotting to analyze 152 Cyto-ID positive candidates. A representative 
blot was shown in Fig. 2C. We found that 124 shRNAs increased LC3B-II intensities by ≥ 1.4-fold based on quan-
tification of protein blots (Fig. 2D and Table S2). We empirically chose 1.4-fold increase of Cyto-ID fluorescence 
or LC3B-II as the cutoff lines because this approach allows us to include autophagy regulators with differential 
capabilities to activate autophagy (see below for details). The strength of autophagy responses often determines 
cell fate. For instance, autophagy often protects cells from cell death; however, a strong response often induces 
excessive autophagy leading to cell death.
To determine whether a specific shRNA is on or off target, we measured knockdown efficiency of 124 shRNAs 
on 122 target genes using quantitative RT-PCR. We found that 83 shRNAs induced a ≥2-fold reduction in mRNA 
levels of 82 genes (Fig. 3A and Table S3). We then selected four candidates and validated knockdown at protein 
levels using commercially available antibodies. shRNAs of ETS2, HCLS1, KRAS and LYN remarkably decreased 
protein expression at a factor of 2 to 5 folds (Fig. 3B–E), congruent with RT-PCR results.
Figure 2. A large-scale RNA interference screen identifies autophagy-regulating genes. (A) Schematic 
diagram illustrating a large-scale RNA interference screen. 336 shRNAs were identified in MDC positive 
cells. (B) Candidate validation using the Cyto-ID spectrophotometric assay. K562 cells were treated with non-
silencing (NS) shRNA or individual 336 candidate shRNAs. The 1.4-fold increase of Cyto-ID fluorescence was 
empirically set as the cut-off line. (C) Candidate validation using the LC3B immunoblotting assay. K562 cells 
were treated with NS or 152 individual shRNAs of Cyto-ID positive candidates. Autophagy was monitored 
using LC3B immunoblotting. A cropped representative blot of LC3B immunoblotting is shown. Full images are 
included in supplemental materials. (D) Quantification of LC3B-II intensities. The intensities of protein bands 
were quantified using Image J. The ratios of the protein intensities of LC3B-II and ACTB are shown. The 1.4-fold 
increase of LC3B-II was empirically set as the cut-off line.
www.nature.com/scientificreports/
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82 candidate genes were hereafter dubbed autophagy-regulating genes (ARGs, Table 1). As mentioned in our 
previous report, ATF5 regulates IM-induced autophagy in BCR-ABL positive CML cells26. The identification 
of ATF5 as an ARG in K562 CML cells indicates that the RNAi screen described above is unbiased. In addi-
tion to ATF5, 19 ARGs (ACAT1, CAMKV, CNOT2, ERGIC1, ETS2, HSF2, IGF2R, JAK1, KRAS, LPCAT2, LYN, 
PAH, PEX2, PLK1, PRKCD, S100A4, SCD, VAMP7, and YWHAZ) were also reported previously as autophagy 
modulators26,36–54. Hence, the remaining 62 ARGs are novel autophagy mediators. The fact that approximately 
one-fourth of ARGs has been reported previously verifies the feasibility of MDC in isolating autophagic cells 
and the rigor of multistep validations in this large-scale RNAi screen. It is also notable that none of the 82 ARGs 
are autophagy-related genes, which are structural proteins or enzymes that directly participate in the formation 
of autophagic compartments such as autophagosomes and autolysosome55. This is perhaps because knockdown 
of autophagy-related genes impairs the formation of autophagic compartments and, therefore, is expected to 
decrease–rather than increase–the levels of MDC, Cyto-ID, or LC3B-II. Hence, a different approach needs to be 
taken to measure activities of autophagy-related genes during autophagy activation or inhibition in future RNA 
interference screens.
Cyto-ID labels most autophagic compartments such as autophagosomes, amphisomes, and autolysosomes34, 
whereas LC3B-II mostly highlights autophagosomes and autolysosomes32,33. Based on the changes in Cyto-ID 
fluorescence (Fig. 2B and Table S1) and LC3B-II intensities (Fig. 2D and Table S2), we defined the ability of ARG 
shRNAs to induce the formation of autophagic compartments using the following criteria: (1) High, if there was 
a ≥ 2-fold increase in both Cyto-ID and LC3B-II; (2) Medium, if there was a ≥ 2-fold increase of either Cyto-ID 
or LC3B-II; (3) Low, if there was a 1.4- to 1.9-fold increase of Cyto-ID and/or LC3B-II. More than half of ARG 
shRNAs was at medium levels, whereas 14 or 22 ARG shRNAs were at high or low levels, respectively (Table S4). 
Hence, ARGs have differential capabilities to modulate autophagy.
Taken together, our genome-wide RNAi screen followed by comprehensive and rigorous validations, identifies 
82 ARGs with different capabilities in regulating autophagy in K562 cells. Of note, 62 candidate ARGs are novel 
autophagy mediators.
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Figure 3. Knockdown efficiency of candidate autophagy-regulating genes (ARGs). (A) Quantitative RT-PCR. 
K562 cells were treated NS or 124 individual shRNAs of Cyto-ID and LC3B-II positive candidates. mRNA 
levels of shRNA-targeting genes were measured using quantitative RT-PCR. The cut-off line was set as 0.5. Error 
bars represent standard deviations from three independent experiments. Protein levels of ETS2 (B), HCLS1 
(G), KRAS (D), and LYN (E) in K562 cells treated with their shRNAs were determined using immunoblotting. 
Cropped images are shown and full images are included in supplemental materials. Protein levels were 
quantified using Image J. ACTB (β actin) is the loading control. Fold changes of ARG protein levels were 
obtained by dividing the ratios of ARG/ACTB in ARG shRNA-treated cells to those in NS shRNA-treated cells.
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Bioinformatic analyses of ARGs. To further characterize ARGs, we performed several bioinformatic 
analyses. We queried the STRING v9.1 database56, which predicts protein-protein interactions. By using 16 core 
autophagy proteins (e.g. ATG3, ATG4, and ATG5, etc.) and LC3B (MAP1LC3B) as the bait (Fig. 4A, in red), we 
found that only two ARG proteins VAMP7 and AGPS (Fig. 4A, in black) showed potential interactions with the 
bait proteins. In line with the result that no autophagy-related genes were found in our RNAi screen, these results 
suggest that ARGs identified herein do not directly participate in the process of autophagy. We then investigated 
whether ARG proteins interact with autophagy signaling molecules. We set 22 known autophagy signaling mole-
cules (Fig. 4B, in red) as the bait and detected potential protein-protein interactions in 13 candidate ARG proteins 
(Fig. 4B, in black). Because 62 ARGs are novel autophagy mediators, there is perhaps a lack of information of 
Gene Symbol Human Gene Descriptions Gene Symbol Human Gene Descriptions
ACAT1* acetyl-Coenzyme A acetyltransferase 1 LPCAT2* lysophosphatidylcholine acyltransferase 2
ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 LYN* v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
AGPS alkylglycerone phosphate synthase MBTPS1 membrane-bound transcription factor peptidase, site 1
AK9 adenylate kinase 9 MESP2 mesoderm posterior 2 homolog (mouse)
AKIP1 A kinase (PRKA) interacting protein 1 MOB3C MOB Kinase Activator 3C
AKR1C3 aldo-keto reductase family 1, member C3 NCS1 Neuronal Calcium Sensor 1
ATF5* activating transcription factor 5 NSDHL NAD(P) dependent steroid dehydrogenase-like
BVES blood vessel epicardial substance PAH* phenylalanine hydroxylase
C1QL3 complement component 1, q subcomponent-like 3 PEX2* Peroxisomal Biogenesis Factor 2
CAMKV* CaM kinase-like vesicle-associated PGLYRP3 peptidoglycan recognition protein 3
CBWD1 COBW domain containing 1 PHF14 PHD finger protein 14
CCDC108 coiled-coil domain containing 108 PIPOX pipecolic acid oxidase
CCDC77 coiled-coil domain containing 77 PLK1* polo-like kinase 1 (Drosophila)
CENPH centromere protein H POLR3D polymerase (RNA) III (DNA directed) polypeptide D, 44 kDa
CLECL1 C-type lectin-like 1 PPP3R2 protein phosphatase 3 (formerly 2B), regulatory subunit B, beta isoform
CLTA clathrin, light chain (Lca) PRKCD* protein kinase C, delta
CNOT2* CCR4-NOT transcription complex, subunit 2 PTDSS1 phosphatidylserine synthase 1
COX11 COX11 homolog, cytochrome c oxidase assembly protein (yeast) RNASEH1 ribonuclease H1
CPXM1 carboxypeptidase X (M14 family), member 1 RP9 retinitis pigmentosa 9 (autosomal dominant)
CUBN cubilin (intrinsic factor-cobalamin receptor) S100A4* S100 calcium binding protein A4
DIRC1 disrupted in renal carcinoma 1 SASH3 SAM and SH3 domain containing 3
DNASE1L1 deoxyribonuclease I-like 1 SCD* stearoyl-CoA desaturase (delta-9-desaturase)
ERGIC1* endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1 SEPT1 septin 1
ERLIN2 ER lipid raft associated 2 SERP1 stress-associated endoplasmic reticulum protein 1
ETS2* v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) SLC25A33 solute carrier family 25, member 33
FABP6 fatty acid binding protein 6, ileal SLC2A8 solute carrier family 2 (facilitated glucose transporter), member 8
FAM13C1 family with sequence similarity 13, member C1 TBX15 T-box 15
FBXO38 F-box protein 38 TCERG1 transcription elongation regulator 1
GGCT gamma-glutamyl cyclotransferase THAP2 THAP domain containing, apoptosis associated protein 2
GH2 growth hormone 2 TNNI3 troponin I type 3 (cardiac)
GLO1 glyoxalase I U2SURP U2 SnRNP-Associated SURP Domain Containing
GPR19 G protein-coupled receptor 19 UBA6 ubiquitin-like modifier activating enzyme 6
GRHL1 grainyhead-like 1 (Drosophila) UTP15 UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. cerevisiae)
GRK4 G protein-coupled receptor kinase 4 VAMP7* vesicle-associated membrane protein 7
HCLS1 hematopoietic cell-specific Lyn substrate 1 VGLL3 vestigial like 3 (Drosophila)
HSF2* heat shock transcription factor 2 WBP1L WW domain binding protein 1-like
IGF2R* insulin-like growth factor 2 receptor YWHAZ* tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide
IGSF1 immunoglobulin superfamily, member 1 ZFP1 zinc finger protein 1 homolog (mouse)
JAK1* Janus kinase 1 (a protein tyrosine kinase) ZNF197 zinc finger protein 197
KRAS* v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ZNF330 zinc finger protein 330
LINC00467 long intergenic non-protein coding RNA 467 ZNF639 zinc finger protein 639
Table 1. Autophagy-regulating genes. *ARGs previously reported as autophagy mediators.
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protein-protein interactions in the database. Hence, these results suggest that ARGs are upstream mediators of 
autophagy process.
By using the DAVID program57, we performed gene ontology analyses. Most ARGs were directly or indirectly 
involved in the signaling pathways emanating from interleukin-3, interleukin-5, or granulocyte-macrophage 
colony-stimulating factor (Fig. 4C). These hematopoietic cytokines play vital roles in leukemogenesis, and are 
important for autophagy regulation in normal and malignant blood cells58–60. Only a few ARGs are implicated 
in mitosis, vesicle biogenesis, diabetes, and lipid metabolism. By querying the GeneCards database, we grouped 
ARGs based on the molecular pathways to which they possibly target. Percentages of ARGs that exhibit potential 
activities in metabolism, transcription, signaling, and molecule transportation were 26%, 18%, 12%, and 10%, 
respectively (Fig. 4D). These molecular pathways have crucial assignments in autophagy regulation55,61,62. These 
results have implications in understanding the relationship between autophagy and ARGs-targeting biological 
processes.
ARGs target different stages of autophagy. Autophagy is a dynamic process (referred to as autophagy 
flux) including initiation (autophagosome formation) and maturation (autolysosome formation and cargo degra-
dation). It is therefore crucial to distinguish whether the changes of autophagic compartments (autophagosomes, 
amphisomes, and autolysosomes) are due to autophagy activation or autophagy flux blockade because levels of 
autophagic compartments increase in both conditions32,33. In our RNAi screen and subsequent analyses, it is 
unclear whether the increase of MDC, Cyto-ID, and LC3B-II levels upon depletion of ARGs is due to the activa-
tion of autophagy initiation or the blockade of autophagy maturation.
To address this question, we employed the Cyto-ID fluorescence spectrophotometric assay. We have success-
fully monitored the changes of autophagic compartments in cells treated with autophagy activators and/or auto-
phagy maturation blockers using this approach34. We treated ARG-deficient cells with chloroquine (an inhibitor 
of autophagy maturation)29,63,64. In principle, activation of autophagy in combination with chloroquine results in 
a significant increase of autophagy compartments compared to each treatment alone. For example, knockdown of 
IGSF1 significantly increased Cyto-ID levels together with chloroquine (P < 0.05; Fig. 5A). Consistently, LC3B-II 
levels also substantially increased in cells treated with IGSF1 shRNA and chloroquine (Fig. 5B). These results 
suggest that IGSF1 suppresses autophagy initiation and its depletion activates autophagy. In contrast, shRNAs of 
PTDSS1 failed to induce a significant increase of Cyto-ID (P = 0.08; Fig. 5C) or LC3B-II (Fig. 5D) in combination 
with chloroquine, compared to PTDSS1 shRNA alone. These results suggest that PTDSS1 targets the autophagy 
maturation stage. We did notice that the Cyto-ID assay detected similar changes in cells treated with either ARG 
shRNAs or chloroquine (Fig. 5A,C), whereas LC3B-II protein levels were much higher in chloroquine-treated 
cells than in ARG shRNAs-treated cells (Fig. 5B,D). This discrepancy may be due to the fact that Cyto-ID meas-
ures levels of most autophagic compartments and LC3B-II only labels autophagosomes. Based on P values that 
determine the statistical significance of difference between means of the combinational treatment (chloroquine 
and shRNA) and those of chloroquine or shRNA (Tables S5 and 2), we found that 57 ARGs significantly enhanced 
the levels of autophagic compartments together with chloroquine, indicating that these ARGs suppress autophagy 
initiation. The remaining 25 ARG shRNAs failed to do so (Tables S5 and 2, in bold).
To further determine whether these 25 ARGs target autophagy maturation stage, we performed a combina-
tional treatment of individual ARG shRNAs and PP242. PP242 is a compound that inhibits mechanistic target of 
rapamycin and launches autophagy65. In principle, knockdown of an ARG that promotes autophagy maturation 
will significantly increase the quantities of autophagic compartments together with PP242. We found that 21 
ARG shRNAs exhibited statistical significance in enhancing the Cyto-ID fluorescence together with PP242 (high-
lighted in bold, Tables S6 and 3). As such, these ARGs facilitate the completion of the autophagy process through 
promoting autophagy maturation. To corroborate these results, we also monitored the changes of another auto-
phagy marker p62 (sequestosome 1, SQSTM1), which is degraded in autolysosomes. Activation of autophagy 
often leads to decreased levels of p62, whereas blockade of autophagy maturation causes accumulation of this pro-
tein. We found that shRNAs of TNNI3, PPP3R2, or MBTPS1 (ARGs that suppress autophagy initiation; Table 2) 
significantly reduced levels of p62 proteins (Fig. 5E). In contrast, p62 protein levels increased in cells treated with 
shRNAs of SLC2A8, RNASEH1, or CBWD1 (Fig. 5F), which impaired autophagy maturation (Tables 2 and 3). To 
further validate our autophagy flux assay presented above, we used BFA1 to block autophagy flux (Fig. 1D–G) 
followed by LC3B immunoblotting. We found that depleting ARGs that target autophagy initiation (e.g. TCERG1, 
ZNF197, or POLR3D) led to a significant increase of LC3B-II levels upon BFA1 treatment (Fig. 5G), whereas 
knockdown of ARGs that target autophagy maturation (e.g. CCDC77, SASH3, or GLO1) failed to do so (Fig. 5H). 
Furthermore, an autophagy flux assay using a combination of imatinib (activating autophagy) and shRNAs of 
ARGs that promote autophagy maturation revealed that depletion of these ARGs significantly increased levels of 
autophagic compartments in combination with IM (Fig. 5I), consistent with PP242 treatment (Table 3).
Of note, shRNAs of four ARGs (ERGIC1, PHF14, TBX15, or UBA6) did not significantly change the levels of 
autophagic compartments together with either chloroquine (Table 2) or PP242 (Tables S6 and 3). One possible 
explanation is that these ARGs may inhibit PP242-induced autophagy, thereby diminishing a further increase of 
Cyto-ID fluorescence in cells upon combinational treatments. ARGs that target autophagy at different stages were 
summarized in Fig. S1. To determine the functional relevance of ARGs in CML, we measured the cytotoxicity 
of IM in K562 cells upon depletion of ARGs. We found that depletion of ARGs that promote autophagy matu-
ration sensitized K562 cells to IM. In contrast, knockdown of ARGs that suppress autophagy initiation showed 
no additive or synergistic inhibition of cell viability (Fig. S2). These results not only provide a further validation 
of candidate ARGs in autophagy regulation, but also highlight the importance of ARGs as potential therapeutic 
targets in CML and other cancers.
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Discussion
In this study, we conducted a large-scale RNAi screen in K562 cells and identified 82 ARGs with 62 candidates 
as novel autophagy mediators. Our further analyses revealed two subclasses of ARGs: ARGs that suppress auto-
phagy initiation and ARGs that promote autophagy maturation (Fig. S1). Identification of new autophagy regula-
tors in cancer cells not only helps understand how autophagy is activated or inhibited, but also provides potential 
drug targets for future therapeutic intervention.
Figure 4. Bioinformatic analyses. (A) Predicted protein-protein interactions between candidate genes and core 
autophagy-related genes using the STRING program. 16 core autophagy-related genes (in red) were used as 
bait in the STRING database. ARGs (black) that show potential interactions with the bait are shown. Each line 
represents a potential interaction from one assay. The size of nodes represents the protein size. (B) Potential 
interactions between candidate genes and kinases in autophagy signaling. (C) Gene term enrichment analysis 
using the DAVID program. The biological processes that were significantly enriched were listed and color-
coded. Each node represents genes involved in these biological processes. The larger the node, the more genes it 
represents. Two nodes are connected if they share genes or have possible interactions. (D) Biological processes 
in which candidate genes are involved. By using the data from the GeneCards database, candidate genes were 
categorized into different biological processes. The percentages of genes involved in these processes are shown.
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RNAi screens have been used previously in mammalian cells to identify genes that regulate autophagy. For 
instance, Chan et al., transiently transfected GFP-LC3B-positive HEK293 cells with small interfering (si) RNAs 
targeting human kinases and searched for kinases that block starvation-induced autophagy66. Following this 
study, Lipinsky et al.,44 and McKnight et al.,67 performed a genome-wide siRNA-based RNAi screen and identi-
fied genes important for autophagy activation during starvation. Several other research groups studied autophagy 
flux or autophagy signaling in unstressed conditions using siRNA or shRNA-based RNAi screening68–71. In these 
screens, LC3B immunoblotting or microscopic imaging of GFP-LC3B or GFP-p62 was used to detect autophagy. 
However, the workload of LC3B immunoblotting of individual shRNA-treated cells in a large-scale RNAi screen 
is overwhelming and time-consuming. Fluorescence imaging of GFP-LC3B or GFP-p62 depends on the avail-
ability of a high content and expensive imaging system. To date, only a few laboratories could afford to use this 
high-content imaging system in large-scale RNAi screens44,67,69,70,72–74.
In this report, we coupled MDC staining with FACS and successfully isolated autophagic K562 cells. Past 
research demonstrates that the specificity of MDC in labeling autophagic cells is relatively low compared to LC3B 
or p62 because this fluorescence dye non-specifically stains lysosomes32,33. However, our results shown in Figs 1, 
2 indicate that MDC staining is at least feasible and efficient in labeling autophagic K562 cells. The sensitivity of 
this approach is equivalent to LC3B immunoblotting and GFP-LC3B fluorescence microscopy. While we could 
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Figure 5. Determination of autophagy stages to which ARGs target. (A,B) Combination of IGSF1 shRNA 
and chloroquine (CQ). K562 cells were treated with NS or IGSF1 shRNA followed by chloroquine treatment. 
Autophagy was assessed using the Cyto-ID spectrophotometric assay (A) or LC3B immunoblotting (B).  
(C,D) Combination of PTDSS1 shRNA and CQ. K562 cells were treated with NS or PTDSS1 shRNA. Autophagy 
was assessed using the Cyto-ID spectrophotometric assay (C) or LC3B immunoblotting (D). (E,F) p62 
immunoblotting. K562 cells treated with NS shRNA or ARG shRNAs were subject to p62 immunoblotting.  
(G) Co-treatment of BFA1 and shRNAs of ARGs that suppress autophagy initiation. K562 cells were transduced 
with viruses harboring NS shRNA or shRNAs of TCERG1, ZNF197, or POLR3D. Cells were then treated with 
5 nM of BFA1 for 48 h. Autophagy was monitored using LC3B immunoblotting. (H) Co-treatment of BFA1 and 
shRNAs of ARGs that promote autophagy maturation. (I). Autophagy flux in K562 cells treated with IM and/or 
shRNAs of ARGs that promote autophagy maturation. K562 cells were transduced with viruses containing NS 
shRNA or shRNAs of ARGs that promote autophagy maturation. Cells were then treated with DMSO (IM−) or 
1 μM of IM (IM+). Autophagy was monitored using the Cyto-ID fluorescence spectrophotometric assay. ACTB 
is the loading control. Images cropped from same blot are shown and full images are included in supplemental 
materials. Error bars represent standard deviations of three independent experiments. *P < 0.05. P values 
determine the difference between combination of IM and ARG shRNA and each treatment alone.
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not rule out the possibility of non-specific staining of non-autophagic K562 cells by MDC in our primary screen, 
our rigorous validations using the Cyto-ID spectrophotometric assay and LC3B immunoblotting assay effectively 
eliminated the false positive candidates. This is supported by the fact that one-fourth of candidate ARGs have 
been reported previously. Hence, using MDC-based FACS to isolate autophagic cells is suitable for performing 
high-content screens (e.g. loss-of-function screens, gain-of-function screens, and small molecule screens, etc.) in 
normal or malignant cells. More importantly, this approach is inexpensive and affordable.
As described earlier, autophagy has multifaceted activities in cancer. On one hand, autophagy protects can-
cer cells from therapy-induced cell death. On the other hand excessive autophagy, by itself, induces cell death 
in cancer cells18. Hence, the determination of autophagy stages to which 82 ARGs target has important clin-
ical implications in treating cancer. For example, 21 ARGs that target the autophagy maturation stage are of 
interest in developing novel combinational therapies in that effectively blocking autophagy maturation inhibits 
autophagy-promoted survival of CML cells, thereby enhancing the sensitivity of CML cells to BCR-ABL inhibi-
tors such as IM29,75. Indeed, our results shown in Fig. S2 demonstrate the functional relevance of ARGs with IM 
sensitivity in K562 cells. Given the possibility of excessive autophagy in inducing cell death, 57 ARGs that sup-
press autophagy initiation are potential new therapeutic targets for CML. Our future research will uncover the 
therapeutic potential of 82 ARGs reported herein in CML or other cancers that benefit from autophagy-related 
therapies.
Methods
Materials and reagents. K562 cells were maintained in RPMI-1640 medium supplemented with 10% fetal 
bovine serum, 100 μg/ml streptomycin, and 100 μg/ml penicillin. The Cyto-ID kit was purchased from Enzo 
Life Sciences. PP242, chloroquine, bafilomycin A1 and monodansylcadaverine (MDC) were purchased from 
Sigma-Aldrich. Imatinib was purchased from LC Laboratories. Stock solutions were prepared as follows: imatinib 
(10 mM) was dissolved in either sterile water or DMSO; PP242 (20 mM) was dissolved in DMSO; chloroquine 
(10 mM) was dissolved in sterile water; bafilomycin A1 (5 mM) was dissolved in DMSO.
Gene 
Symbols
P values
Gene 
Symbols
P values
Gene 
Symbols
P values
Combo 
vs shRNA
Combo 
vs CQ
Combo vs 
shRNA
Combo 
vs CQ
Combo vs 
shRNA
Combo 
vs CQ
ACAT1 <0.01 <0.01 GGCT <0.01 0.09 PPP3R2 0.04 0.01
ADAMTS2 0.04 <0.01 GH2 <0.01 <0.01 PRKCD 0.01 0.04
AGPS 0.03 0.01 GLO1 0.01 0.15 PTDSS1 0.08 0.02
AK9 0.02 <0.01 GPR19 0.02 <0.01 RNASEH1 0.02 0.41
AKIP1 <0.01 <0.01 GRHL1 0.02 <0.01 RP9 0.01 <0.01
AKR1C3 0.08 <0.01 GRK4 0.07 0.02 S100A4 0.04 <0.01
ATF5 <0.01 <0.01 HCLS1 <0.01 0.02 SASH3 0.07 <0.01
BVES 0.01 0.03 HSF2 0.01 0.06 SCD <0.01 <0.01
C1QL3 <0.01 0.42 IGF2R <0.01 <0.01 SEPT1 0.04 <0.01
CAMKV <0.01 <0.01 IGSF1 0.02 <0.01 SERP1 <0.01 <0.01
CBWD1 <0.01 0.12 JAK1 0.01 <0.01 SLC25A33 0.03 <0.01
CCDC108 <0.01 0.01 KRAS 0.02 <0.01 SLC2A8 0.13 0.02
CCDC77 0.11 <0.01 LINC00467 <0.01 <0.01 TBX15 0.05 0.21
CENPH <0.01 <0.01 LPCAT2 <0.01 0.02 TCERG1 <0.01 0.02
CLECL1 <0.01 <0.01 LYN <0.01 <0.01 THAP2 0.01 <0.01
CLTA <0.01 <0.01 MBTPS1 0.01 <0.01 TNNI3 <0.01 <0.01
CNOT2 0.02 <0.01 MESP2 <0.01 <0.01 U2SURP 0.06 0.02
COX11 0.01 0.28 MOB3C 0.13 0.04 UBA6 0.06 <0.01
CPXM1 <0.01 <0.01 NCS1 <0.01 <0.01 UTP15 0.02 <0.01
CUBN 0.01 <0.01 NSDHL <0.01 0.04 VAMP7 <0.01 <0.01
DIRC1 0.02 <0.01 PAH <0.01 <0.01 VGLL3 0.01 <0.01
DNASE1L1 0.08 <0.01 PEX2 0.01 <0.01 WBPL1 0.02 <0.01
ERGIC1 0.06 <0.01 PGLYRP3 0.06 <0.01 YWHAZ 0.01 0.12
ERLIN2 0.01 <0.01 PHF14 0.02 0.14 ZFP1 0.16 <0.01
ETS2 0.02 <0.01 PIPOX 0.04 <0.01 ZNF197 <0.01 <0.01
FABP6 <0.01 <0.01 PLK1 0.07 <0.01 ZNF330 0.02 <0.01
FAM13C1 0.02 0.47 POLR3D <0.01 <0.01 ZNF639 <0.01 <0.01
FBXO38 <0.01 <0.01
Table 2. Effect of ARG shRNAs and chloroquine on the formation of autophagic compartments. Note: Combo 
indicates the combinational treatment of shRNA and chloroquine (CQ). P values of combo vs CQ or combo vs 
shRNA indicate whether the increase of Cyto-ID levels in cells treated with combo is significantly higher than 
Cyto-ID levels in cells treated with either CQ or shRNA. ARGs with a P value larger than 0.05 are highlighted in 
bold. Means and standard deviations of each treatment were shown in Table S5.
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Fluorescence microscopy. Fluorescence microscopy was used to monitor MDC fluorescence and 
GFP-LC3B. For MDC fluorescence microscopy, K562 cells were treated with a low dose of imatinib (1 μM) to 
induce autophagy26 or 5 nM of bafilomycin A1 to block autophagy flux. Cells were then stained with 0.1 mM 
MDC for 10 minutes in the dark at 37 °C as described previously31. Live MDC positive cells were imaged using 
an inverted fluorescence microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY). Photos were taken using a 
20× or 40× lens at different exposure times (from 100 to 200 milliseconds). For GFP-LC3B microscopy, K562 
cells were stably transfected with a pEGFP-LC3B plasmid that encodes a fusion protein GFP-LC3B. Cells were 
then treated with imatinib (1 μM) for 18 hours and/or BFA1 (5 nM) for 48 hours. GFP fluorescence images were 
taken using a TCS SP8 laser scanning confocal microscope equipped with a Plan Apochromat 63×/1.4 numerical 
aperture oil immersion objective, and a Leica HyD hybrid detector (Leica, Buffalo Grove, IL).
Quantification of cells with GFP-LC3B puncta. Four to five images of more than 30 K562 cells treated 
with DMSO, 1 μM imatinib, and/or 5 nM bafilomycin A1 were randomly selected. GFP-LC3B-expressing K562 
cells or K562 cells with GFP-LC3B puncta (indicating the formation of autophagosomes) in these images were 
counted by three persons. Percentages of cells with GFP-LC3B puncta were obtained by dividing numbers of cells 
with GFP-LC3B puncta with those of GFP-LC3B-expressing cells. The statistical difference was obtained using 
the Student’s t test.
Fluorescence spectrophotometric assay. The MDC or Cyto-ID fluorescence spectrophotometric assay 
was previously described34,35. In brief, autophagy was induced or inhibited in K562 cells as described in each 
figure. To minimize spontaneous autophagy due to lack of nutrients, cells were seeded in freshly prepared media 
at 5 × 104 or 105 cells per ml overnight. Live autophagic cells were stained with MDC as described above or with 
Cyto-ID based on the manufacturer’s instructions (Enzo Life Sciences, Inc.). Cells were then seeded in a 96-well 
plate and fluorescence intensity was quantified using a microplate reader (Molecular Devices, Sunnyvale, CA). 
The wavelengths used for detecting MDC fluorescence were 335 nm (excitation) and 525 nm (emission), respec-
tively. The Cyto-ID fluorescence was measured at excitation 485 nm and emission 535 nm. Fluorescence levels 
were shown as fold changes by normalizing fluorescence intensities in cells treated with bafilomycin A1, imatinib, 
Gene Symbol
P values
Combo vs PP242 Combo vs shRNA
AKR1C3 0.030 0.01
C1QL3 <0.01 <0.01
CBWD1 <0.01 <0.01
CCDC77 <0.01 <0.01
COX11 <0.01 <0.01
DNASE1L1 <0.01 <0.01
ERGIC1 0.425 <0.01
FAM13C1 0.01 <0.01
GGCT 0.047 <0.01
GLO1 <0.01 <0.01
GRK4 <0.01 <0.01
HSF2 0.024 <0.01
MOB3C <0.01 <0.01
PGLYRP3 <0.01 <0.01
PHF14 0.096 <0.01
PLK1 0.025 <0.01
PTDSS1 <0.01 <0.01
RNASEH1 <0.01 <0.01
SASH3 <0.01 <0.01
SLC2A8 0.049 <0.01
TBX15 0.095 0.111
U2SURP <0.01 <0.01
UBA6 0.266 <0.01
YWHAZ <0.01 <0.01
ZFP1 <0.01 <0.01
Table 3. Effect of ARG shRNAs and PP242 on the formation of autophagic compartments. Note: Combo 
indicates the combinational treatment of shRNA and PP242. P values of combo vs PP242 or combo vs shRNA 
indicate whether the increase of Cyto-ID levels in cells treated with combo (PP242 + shRNA) is significantly 
higher than Cyto-ID levels in cells treated with either PP242 or shRNA. ARGs with P values larger than 0.05 
are not highlighted in bold. Means and standard deviations of each treatment were shown in Table S6.
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or shRNAs to those in untreated or non-silencing (NS) shRNA-treated cells. There were three biological replicates 
in each treatment group. The statistical difference was obtained using the Student’s t test.
Lentivirus production. shRNAs used in this study were built on the pLKO.1 lentiviral vector. To produce 
lentivirus that harbors a library of about 75,000 shRNAs targeting 15,000 human genes (OpenBiosystem, GE 
Dharmacon), shRNA plasmids were divided into 16 pools and used to transfect HEK293T cells using effectene 
(QIAGEN). 2 μg of plasmid DNA was used to transfect 5 × 106 cells to yield 3 ml media containing lentivirus. A 
series of dilution of viral supernatant was then used to transduce HEK293T cells and puromycin (0.25 μg/ml) was 
used to select infected cells. Based on cell colonies stained by crystal violet (Sigma-Aldrich), the titer of lentivirus 
was determined.
RNA interference screening for autophagy-regulating genes. 2 × 105 K562 cells were transduced 
with above 16 pools of lentiviruses at a multiplicity of infection (MOI) of 2.5 using the standard spinning infec-
tion approach. The volume of viruses was calculated using the formula: (MOI × cell number)/titer. Infected cells 
were then selected with 0.5 μg/ml puromycin for 1 week to facilitate the insertion of shRNAs into the host cell 
genome. Cells were stained with 0.1 mM MDC (Sigma-Aldrich) for 10 minutes in dark at 37 °C. Cells with strong 
MDC fluorescence (top 1%) were collected using FACS (wavelength: excitation 335 nm and emission 525 nm). 
Genomic DNA was isolated immediately after FACS using the QIAmp DNA mini kit (QIAGEN). DNA fragments 
that contained shRNA sequences were amplified using PCR as previously described76. The primer set used for 
this reaction was (Forward: 5′-acgatacaaggctgttagagag-3′; Reverse: 5′-cgaaccgcaaggaaccttc-3′). The PCR prod-
ucts were the cloned into a TA vector (Thermo Fisher Scientific) and submitted for Sanger DNA sequencing. 
The sequencing primer was 5′-aaacccagggctgccttggaaaag-3′. shRNAs were identified by searching the database 
RNAi codex. To help identify as many candidates as possible, 500 PCR-amplified DNA fragments were sent for 
sequencing. Among 500 sequences, 336 different shRNAs were identified and more than 50 shRNAs were repeat-
edly sequenced at least one more time, suggesting that nearly all PCR-amplified shRNAs in autophagic K562 cells 
have been identified in our screen. Primary candidates were further validated using the Cyto-ID fluorescence 
spectrophotometric assay and LC3B immunoblotting. For experiments involving individual shRNAs, lentivirus 
was prepared as described above. K562 cells were transduced with viruses with NS shRNA or candidate shRNAs 
followed by 1-week puromycin (0.1–0.5 μg/ml) selection.
Immunoblotting. Immunoblotting was performed as previously reported34,77. Antibodies used in this 
study include: anti-LC3B (Cell Signaling Technology®, 1:1000), anti-ACTB (β-actin) (Sigma-Aldrich, 1:5000) 
anti-KRAS, anti-LYN (Cell Signaling Technology®, 1:1000), anti-HCLS1 (Cell Signaling Technology®, 1:1000), 
anti-PLK1 (Cell Signaling Technology®, 1:1000), and anti-ETS2 (Santa Cruz Biotechnology, Inc., 1:200). 
Quantification of protein brand intensities was performed using Image J as described previously34. The band 
intensities of proteins of interest were first normalized to that of actin (ACTB), yielding relative intensities. The 
relative intensities of proteins of interest in candidate shRNA-treated cells were further normalized with that in 
NS shRNA-treated cells.
Quantitative RT-PCR. mRNA levels of genes of interest were measured using qRT-PCR as described pre-
viously76,78. In brief, K562 cells treated with NS shRNA or individual candidate shRNAs were subject to total 
RNA isolation using Trizol (Thermo Fisher Scientific). 1 to 5 μg total RNA was used to generate cDNA using 
SuperScript III reverse transcriptase (Thermo Fisher Scientific). The mRNA levels of each candidate gene were 
determined using quantitative real-time PCR.
Bioinformatic analyses. Potential protein-protein interaction was analyzed using the online program 
STRING v9.1 (http://string-db.org). Bait proteins included (1) proteins that directly participate in the autophagy 
process and (2) kinases that regulate autophagy. Results were exported as image files and modified using adobe 
illustrator. Lines between nodes represent potential interactions. Colors denote different assays. Gene ontology 
analyses were performed using the online program DAVID (https://david.ncifcrf.gov) or GeneCards database.
Autophagy stage determination assay. Autophagy stage determination assay was previously 
described34,35. K562 cells that stably express NS shRNA or individual candidate shRNAs were treated with either 
vehicle (water or DMSO), chloroquine (2.5 μM for 6 hours), or bafilomycin A1 (5 nM for 48 hours). In some cases, 
these cells were treated with DMSO, PP242 (5 μM), or imatinib (1 μM) for 8–10 hours. The amount of autophagic 
compartments was measured using the Cyto-ID fluorescence spectrophotometric assay or LC3B immunoblotting 
as described above. The Cyto-ID level in cells treated with the combinations was compared to that of each treat-
ment alone. The statistical difference was obtained using the Student’s t test.
Data availability. All data are available for sharing upon request.
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